Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

695761.pdf (884.46 KB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2020-02-08

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/160529

Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1111/tmi.13382

Resum

Canine leishmaniosis is an important vector-borne zoonosis caused mainly by Leishmania infantum. Diagnosis and treatment of affected individuals can be particularly complex, hindering infection control in endemic areas. Methods to prevent canine leishmaniosis include the use of topical insecticides, prophylactic immunotherapy and vaccination. Four vaccines against canine leishmaniosis have been licensed since 2004, two in Brazil (Leishmune®, the production and marketing license of which was withdrawn in 2014, and Leish-Tec®) and two in Europe (CaniLeish® and LetiFend®). After several years of marketing, doubts remain regarding vaccine efficacy and effectiveness, potential infectiousness of vaccinated and infected animals or the interference of vaccine-induced antibodies in L. infantum serological diagnosis. This review summarizes the scientific evidence for each of the vaccines commercially approved for canine leishmaniosis, while discussing possible weaknesses of these studies. Furthermore, it raises the need to address important questions related to vaccination impact in Leishmania-endemic countries and the importance of post-marketing pharmacological surveillance.

Matèries

Leishmaniosi, Vacunes

Matèries (anglès)

Leishmaniasis, Vaccines

Citació

Col·leccions

Articles publicats en revistes (Biologia, Sanitat i Medi Ambient)
Articles publicats en revistes (ISGlobal)

Citació

VÉLEZ, Rita and GÁLLEGO CULLERÉ, M. (Montserrat). Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy. Tropical Medicine & International Health. 2020. Vol. 25, num. 5, pags. 540-557. ISSN 1360-2276. [consulted: 16 of August of 2026]. Available at: https://hdl.handle.net/2445/160529

Exportar metadades

JSON - METS

Compartir registre